Outcomes and Predictors of Survival for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Large Population-Based Analysis

被引：0
|
作者：
Gong, Inna [1 ]
Crump, Michael [1 ]
Prica, Anca [1 ]
Calzavara, Andrew [2 ]
Liu, Ning [3 ]
Rodin, Danielle [4 ]
Hodgson, David [5 ]
Mozessohn, Lee [6 ]
Cheung, Matthew C. [6 ]
Kuruvilla, John [7 ]
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[2] Inst Clin Evaluat Sci ICES, Toronto, ON, Canada
[3] ICES, Toronto, ON, Canada
[4] Princess Margaret Canc Ctr, Radiat Med Program, Toronto, ON, Canada
[5] Princess Margaret Canc Ctr, Dept Radiat Oncol, Toronto, ON, Canada
[6] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
[7] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-206056
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3092 / 3093
页数：2
相关论文
共 50 条
  • [41] Relapsed or Refractory Diffuse Large B-Cell Lymphoma: "Dazed and Confused"
    Kesireddy, Meghana
    Lunning, Matthew A.
    ONCOLOGY-NEW YORK, 2022, 36 (06): : 360 - 369
  • [42] Novel agents in relapsed/refractory diffuse large B-cell lymphoma
    Varma, Gaurav
    Goldstein, Jordan
    Advani, Ranjana H.
    HEMATOLOGICAL ONCOLOGY, 2023, 41 : 92 - 106
  • [43] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M.
    Zenz, T.
    Rosler, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 66 - 67
  • [44] Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
    Salles, Gilles
    Dlugosz-Danecka, Monika
    Ghesquieres, Herve
    Jurczak, Wojciech
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (04) : 455 - 463
  • [45] Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Sehn, Laurie H.
    Herrera, Alex F.
    Flowers, Christopher R.
    Kamdar, Manali K.
    McMillan, Andrew
    Hertzberg, Mark
    Assouline, Sarit
    Kim, Tae Min
    Kim, Won Seog
    Ozcan, Muhit
    Hirata, Jamie
    Penuel, Elicia
    Paulson, Joseph N.
    Cheng, Ji
    Ku, Grace
    Matasar, Matthew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 155 - +
  • [46] Bendamustine/rituximab in relapsed or refractory diffuse large B-cell lymphoma
    Vacirca, J. L.
    Acs, P. I.
    Shimkus, B. J.
    Rosen, P. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma
    Goparaju, Krishna
    Caimi, Paolo F.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (11) : 1373 - 1381
  • [48] TREATMENT PATTERNS AND COST ANALYSIS AMONG PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
    Nabhan, C.
    Myerscough, C.
    Kish, J.
    Chung, J.
    Chopra, D.
    VALUE IN HEALTH, 2019, 22 : S82 - S82
  • [49] Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis
    Merchionne, Francesca
    Quintana, Giovanni
    Gaudio, Francesco
    Minoia, Carla
    Specchia, Giorgina
    Guarini, Attilio
    Quarta, Giovanni
    Pavone, Vincenzo
    Melpignano, Angela
    LEUKEMIA RESEARCH, 2014, 38 (12) : 1446 - 1450
  • [50] Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma
    Miller, Sally D.
    Lozano-Ortega, Greta
    Mutebi, Alex
    Briggs, Owanate
    Sail, Kavita
    Elliott, Brian
    Kalsekar, Anupama
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (01)
12345